CARDURA Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Cardura, and when can generic versions of Cardura launch?

Cardura is a drug marketed by Viatris and is included in two NDAs.

The generic ingredient in CARDURA is doxazosin mesylate. There are fourteen drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the doxazosin mesylate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Cardura

A generic version of CARDURA was approved as doxazosin mesylate by APOTEX on October 18^th, 2000.

Try a Trial

Summary for CARDURA

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	106
Clinical Trials:	11
Patent Applications:	1,730
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CARDURA
What excipients (inactive ingredients) are in CARDURA?	CARDURA excipients list
DailyMed Link:	CARDURA at DailyMed

Drug patent expirations by year for CARDURA

Recent Clinical Trials for CARDURA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
The University of Texas Health Science Center, Houston	Phase 1
Brown University	Phase 2
University of California, Los Angeles	Phase 3

See all CARDURA clinical trials

Pharmacology for CARDURA

Drug Class	alpha-Adrenergic Blocker
Mechanism of Action	Adrenergic alpha-Antagonists

Anatomical Therapeutic Chemical (ATC) Classes for CARDURA

C02CA	Alpha-adrenoreceptor antagonists
C02C	ANTIADRENERGIC AGENTS, PERIPHERALLY ACTING
C02	ANTIHYPERTENSIVES
C	Cardiovascular system

US Patents and Regulatory Information for CARDURA

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-001	Nov 2, 1990	AB	RX	Yes	Yes	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-004	Nov 2, 1990	AB	RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-002	Nov 2, 1990	AB	RX	Yes	No	⤷ Try a Trial	⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for CARDURA

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-003	Nov 2, 1990	⤷ Try a Trial	⤷ Try a Trial
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-001	Nov 2, 1990	⤷ Try a Trial	⤷ Try a Trial
Viatris	CARDURA	doxazosin mesylate	TABLET;ORAL	019668-004	Nov 2, 1990	⤷ Try a Trial	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for CARDURA

See the table below for patents covering CARDURA around the world.

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Title	Estimated Expiration
Latvia	5254	4-amino-2-(piperazin-1-il)-vai 4-amino-2-(homopiperazin-1-il)hinazolina atvasinajumu vai to farmaceitiski pienemamu saju-skabju iegusanas panemiens	⤷ Try a Trial
Sweden	7811382		⤷ Try a Trial
Egypt	13594	PIPERAZINYL QUINAZOLINE DERIVATIVES AS ANTIHPERTENSIVES	⤷ Try a Trial
>Country	>Patent Number	>Title	>Estimated Expiration

Summary for CARDURA

Recent Clinical Trials for CARDURA

Pharmacology for CARDURA

Anatomical Therapeutic Chemical (ATC) Classes for CARDURA

Make Better Decisions: Try a trial or see plans & pricing